Your session is about to expire
← Back to Search
Allogeneic CAR-T Cells for Cancer
Study Summary
This trial is testing a new cancer treatment in adults with advanced or metastatic epithelial-derived solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a genetic predisposition to HLH/MAS.I have a history of serious liver problems.I have taken or will need immunosuppressive drugs recently or during the study.I am 18 or older and expected to live more than 3 months.My cancer has grown or spread after my last treatment and can be measured.You need to have a sample of your tumor stored or agree to have a small piece of your tumor removed for testing.I am mostly active and can care for myself.I have cancer that has spread to my brain.I have taken cancer medication within the last 2 weeks.My cancer cannot be surgically removed, has spread, and does not respond to standard treatments.I have recovered from side effects of previous treatments.You must have a negative pregnancy test before starting the treatment.My vital organs are functioning well.You do not have suitable veins for receiving medication or taking blood samples.I have taken steroids within a week of starting the study or might need them during it.I currently have an active infection.I have had a serious brain condition like a stroke or epilepsy.You have a history of an autoimmune disease or currently have one.I have another cancer besides the one being studied, but it's not a low-risk type like non-spreading skin cancer.I have severe heart issues, including heart failure or a recent heart attack.
- Group 1: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)
- Group 2: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)
- Group 3: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
- Group 4: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many volunteers have registered for this medical experiment?
"Poseida Therapeutics, Inc., the entity responsible for this research project, must identify 100 individuals that meet the protocol's eligibility requirements. The trial will be conducted in multiple sites including MD Anderson Cancer Center (Houston, Texas) and University of California, San Francisco (San Francisco, California)."
Are there any openings for this research endeavor at the present?
"According to clinicaltrials.gov, this medical trial is actively recruiting participants at the time of writing. The initial posting was on February 15th 2022 and it has been adjusted lastly on October 26th 2022."
What regulatory approval has P-MUC1C-ALLO1 CAR-T cells obtained?
"Due to the limited amount of data corroborating its efficacy and safety, P-MUC1C-ALLO1 CAR-T cells has been ranked a 1 on our team's scale."
What is the geographic distribution of this experiment?
"This medical study has opened enrolment at 5 distinct locations, including MD Anderson Cancer Center in Houston and NEXT Oncology in San Antonio. Additionally, there are 3 other sites participating such as University of California – San Francisco."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger